Atopic Dermatitis

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate-to-severe atopic dermatitis for young children 6 months to 5 years old.

Investigators detailed personally mediated, institutional, and internalized antiracism practices that could be applicable to medicine.

Practice separation is occurring more frequently in medium- and large-sized practice groups and among early- and late-career dermatologists.

New data from the ECZTRA 6 trial noted improvements in itch, sleep interference, anxiety and more.

The recent FDA approval of the oral JAK inhibitor could change the landscape of atopic dermatitis management.

A total of 45 studies were selected for the systematic review, with non-White patients being underrepresented across them all.

Investigators added that the meta-analysis contributed to the comparative effectiveness literature for AGA therapies regarding the compared interventions.

While reporting for race and ethnicity in US studies had increased from 59.8% to 71.9%, the proportion of articles including at least 20% non-White representation remained unchanged.

After its approval by the FDA, no new safety findings were reported on weekly dosing of the biologic.

Investigators note that validation of these biomarkers would require multi-center and independent validation of the current findings.

There are currently no approved systemic treatments for prurigo nodularis, but patients treated with dupilumab experienced significantly greater improvements in measures of overall health-related quality of life, skin pain, and symptoms of anxiety and depression.

Swedish investigators noted differences in the prevalence of atopic dermatitis among the 2 sexes, and considered it important data for clinicians that treat patients with the disease.

Investigators believe drugs like etanercept and ustekinumab could reduce the risk of psoriatic arthritis in patients with moderate-to-severe chronic plaque psoriasis.

Investigators in China observed a substantial decrease in the number of severe cases after the arrival of the EV-A71 vaccine.

The decision was supported by 5 clinical trials that resulted in significant improvements in skin clearance, extent of disease, and severity.

Upadacitinib is now indicated for children 12 years and older, and can be used as a monotherapy or with topical corticosteroids.

Trials of CBP-201 for asthma and chronic rhinosinusitis with nasal polyps are ongoing, and early data from the atopic dermatitis trial were promising.

The skin disease was also linked to higher levels of glucosyl cholesterol which was strongly associated with disease severity.

The results suggested that the microbial changes were secondary in the pathogenesis of the skin disease.

Dr. Silverberg speaks of the recent FDA approval of the biologic for patients with moderate-to-severe atopic dermatitis.

Previous studies suggested that the disorder is caused by immunoglobulin G (IgG) antibodies against the NC16A domain of collagen XVII.

Recovery was often deemed rapid, with patients reporting post-surgical pain to be less severe than the pain of their disease.

A new investigation, which included the largest AGEP study cohort, concluded that the disease was also typically triggered by antimicrobials.

Treatment with the antibody also resulted in infections and drug reactions, prompting a call for larger and longer studies from investigators.

Investigators hypothesized that red cell distribution width to hemoglobin ratio could help in stratifying the risk of the skin condition in patients form the Singapore General Hospital.